TMates vs CoreAgeRx: Pricing, access, and drug options compared
TMates vs CoreAgeRx: which online GLP-1 option fits you depends on price, clinician access, and whether you want semaglutide only or tirzepatide options. Early verdict: TMates emphasizes 24/7 U.S. doctor access and a flat $199/month every dose, while CoreAgeRx emphasizes lower monthly pricing and same-price-every-month plans including semaglutide at $79/month and tirzepatide at $129/month.
Explore TMates $199/month plan
Side by side: top differences between TMates and CoreAgeRx
This comparison uses the specific claims captured for each provider. The three most distinctive differences are pricing structure, clinician availability, and drug selection and dosing options. Both providers note that treatment is subject to clinician review and that compounded medications are not FDA approved where that was stated.
1) Pricing model and listed monthly rates
TMates lists a flat price of $199/month, every dose, with the provider repeatedly emphasizing no step up fees as dosage escalates. CoreAgeRx markets “Same Price. Every Month.” with semaglutide listed at $79/month and tirzepatide listed at $129/month and states no membership fees or unexpected price hikes. Both vendors present a flat monthly approach, but the listed monthly amounts differ materially.
See CoreAgeRx semaglutide and tirzepatide pricing
2) Clinician access and visit model
TMates highlights 24/7 access to U.S.-based doctors across all 50 states and virtual check-in appointments for ongoing oversight. CoreAgeRx emphasizes a brief 3-minute online visit and clinician review but captured details do not verify 24/7 physician availability. If continuous physician access matters, the two providers present different support claims in the captured material.
Check TMates clinician access details
3) Drug selection, dosing caps, and product type
TMates in the captured content offers clinically dosed compounded semaglutide formulated in U.S. facilities and notes compounded medications are not FDA approved. CoreAgeRx lists both tirzepatide up to 7.5 mg and semaglutide up to 1.0 mg at fixed monthly prices and also includes the regulatory qualifier that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
Quick comparison table
| Criteria | TMates | CoreAgeRx |
|---|---|---|
| Starting price listed | $199/month, every dose | Semaglutide $79/month; Tirzepatide $129/month |
| Pricing model | Flat $199/month at every dose; no step-up fees | Same price every month; no membership fee |
| Clinician access | 24/7 U.S. doctor access, virtual check-ins | 3-minute online visit; clinician review |
| Drug options | Clinically dosed compounded semaglutide (U.S. formulated) | Semaglutide up to 1.0 mg and tirzepatide up to 7.5 mg listed |
| State coverage | Licensed coverage in all 50 states noted | Captured details did not verify state coverage; eligibility subject to clinician review |
| Regulatory note | Compounded medications are not FDA approved and not reviewed by FDA | Medication-specific approval status must be confirmed; branded and compounded products are not interchangeable |
Other practical differences captured
TMates emphasizes U.S.-formulated medications, shipping to most states and accepts direct payment rather than billing insurance in the captured FAQ content. CoreAgeRx highlights avoiding membership fees and billing surprises and urges users to confirm eligibility, pharmacy, state coverage and renewal terms because those details may change or were not fully published on the captured page.
Review CoreAgeRx enrollment and eligibility
Both providers note that treatment is available only when a licensed clinician determines it is medically appropriate. Both include regulatory qualifiers about compounded medications when applicable. The captured material for TMates also says they accept most major insurance plans in general but operates on a direct-pay model for the services described; CoreAgeRx states no insurance is required on the landing page capture.
Start with TMates clinician-supervised program
Conclusion: TMates vs CoreAgeRx
In short, TMates vs CoreAgeRx boils down to tradeoffs between higher listed monthly pricing with 24/7 U.S. doctor access and broader state licensing at TMates, versus lower listed monthly rates and explicit same-price-every-month marketing at CoreAgeRx with both semaglutide and tirzepatide listed. Both note clinician review and regulatory qualifiers about compounded products in the captured content.
Choose TMates if you want 24/7 access to U.S.-based doctors, U.S. formulated compounded semaglutide, licensed coverage in all 50 states and a flat $199/month rate with no step-up fees as dosage escalates.
Choose CoreAgeRx if you prioritize lower listed monthly pricing, same-price-every-month messaging, and explicit listed options for semaglutide at $79/month or tirzepatide at $129/month while confirming eligibility, state coverage and renewal terms with the clinician-reviewed offer.